CANCER resistance surveillance program: Initial results from hematology-oncology centers in North America

Annals of Pharmacotherapy

Volumn 37, Issue 1, 2003, Pages 47-56

  Mutnick, Alan H ^a,b   Kirby, Jeffrey T ^a   Jones, Ronald N ^c  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial resistance; Neutropenia; Surveillance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFAZOLIN; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLAVULANIC ACID; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PENICILLIN G; PIPERACILLIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; TETRACYCLINE; TICARCILLIN; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; CITROBACTER; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CORYNEBACTERIUM; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; HEALTH SURVEY; KIDNEY INFECTION; KLEBSIELLA; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; RESPIRATORY TRACT INFECTION; SERRATIA; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; YEAST;

EID: 0037224612     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C292     Document Type: Article

References (30)

1. Jones RN. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999;29:495-502.
2. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490-4.
3. Bodey GP. Management of persistent fever in the neutropenic patient. Am J Med 2000;108:343-5.
4. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T. et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
5. Blijlevens NMA, Donnelly JP, de Pauw BE. Empirical therapy of febrile neutropenic patients with mucositis: Challenge of risk-based therapy. Clin Microbiol Infect 2001;7(suppl 4):47-52.
6. Gross PA, Pujat D. Implementing practice guidelines for appropriate antimicrobial usage: A systematic review. Med Care 2001;39(8 suppl 2): II55-69.
7. Pfaller MA, Jones RN, Doern GV, Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada). Antimicrob Agents Chemother 1998;42:1762-70.
8. Kollef M. Antimicrobial therapy of ventilator-associated pneumonia. Chest 1999;115:8-11.
9. Jarvis W. Selected aspects of the socioeconomic impact of nosocomial infections: Morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol 1996;17:552-7.
10. Ibrahim E, Sherman G, Ward S, Fraser V, Kollef M. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55.
11. Bax R, Bywater R, Cornaglia G, Goossens H, Hunter P, Isham V, et al. Surveillance of antimicrobial resistance - What, how and whither? Clin Microbiol Infect 2001;7:316-25.
12. National Committee for Clinical Laboratory Standards (NCCLS). Methods for Dilution Antimicrobial Tests for Bacteria that Grows Aerobically. Approved Standard M7-A5. Wayne, PA: NCCLS, 2000.
13. National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing. Supplemental Tables, M100-S12. Wayne, PA: NCCLS, 2002.
14. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretive criteria and quality control guidelines. J Clin Microbiol 2001;39:183-90.
15. Rolston KV. Expanding the options for risk-based therapy in febrile neutropenia. Diagn Microbiol Infect Dis 1998;31:411-6.
16. Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R. Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002;34:1469-74.
17. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002;34:1524-9.
18. Tallent SM, Bischoff T, Climo M, Ostrowsky B, Wenzel RP, Edmond MB. Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections. J Clin Microbiol 2002;40:2249-50.
19. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: Results from the SENTRY Antimicrobial Surveillance Program. 1997-1999. Clin Infect Dis 2001;32(suppl 2):S133-45.
20. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-12.
21. Luzzaro F, Perilli M, Amicosante GL, Belloni R, Zollo A, Bianchi C, et al. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations. Int J Antimicrob Agents 2001;17:131-5.
22. Swartz MN. Hospital-acquired infections: Diseases with increasingly limited therapies. Proc Natl Acad Sci 1994;91:2420-7.
23. Bonnet R, De Champs C, Sirot D, Chanal C, Labia R, Sirot J. Diversity of TEM mutants in Proteus mirabilis. Antimicrob Agents Chemother 1999;43:2671-7.
24. Chanal C, Bonnet R, De Champs C, Sirot D, Labia R, Sirot J. Prevalence of beta-lactamases among 1,072 clinical strains of Proteus mirabilis: A 2-year survey in a French hospital. Antimicrob Agents Chemother 2000;44:1930-5.
25. De Champs C, Bonnet R, Sirot D, Chanal C, Sirot J. Clinical relevance of Proteus mirabilis in hospital patients: A two year survey. J Antimicrob Chemother 2000;45:537-9.
26. Mariotte S, Nordmann P, Nicolas MH. Extended-spectrum β-lactamase in Proteus mirabilis. J Antimicrob Chemother 1994;33:925-35.
27. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001;32(suppl 2):S94-103.
28. Pfaller MA, Jones RN. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: Resistance implications in the treatment of serious infections. J Antimicrob Chemother 2002;46:25-37.
29. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282-9.
30. Corey L, Boeckh M. Persistent fever in patients with neutropenia. N Engl J Med 2002;346:222-4.